Recent advances include the generation of a tau knockout mouse (tauΔex1) line using CRISPR/Cas9 targeting the MAPT gene, which overcame the limitations of earlier embryonic stem cell-based models and exhibited reduced seizure susceptibility without cognitive impairment [188]. This evidence concerns the gene MAPT and Cognitive impairment.